nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—epilepsy syndrome	0.112	0.529	CbGaD
Sulindac—ALB—epilepsy syndrome	0.1	0.471	CbGaD
Sulindac—ALB—Oxcarbazepine—epilepsy syndrome	0.0395	0.0974	CbGbCtD
Sulindac—ALB—Fosphenytoin—epilepsy syndrome	0.0346	0.0851	CbGbCtD
Sulindac—ALB—Clonazepam—epilepsy syndrome	0.0313	0.077	CbGbCtD
Sulindac—CYP1A1—Propofol—epilepsy syndrome	0.0278	0.0685	CbGbCtD
Sulindac—CYP1A1—Phenobarbital—epilepsy syndrome	0.0266	0.0655	CbGbCtD
Sulindac—ALB—Rufinamide—epilepsy syndrome	0.0255	0.0628	CbGbCtD
Sulindac—PTGS1—Diazepam—epilepsy syndrome	0.0252	0.0621	CbGbCtD
Sulindac—SLC22A6—Acetazolamide—epilepsy syndrome	0.0233	0.0574	CbGbCtD
Sulindac—ALB—Phenytoin—epilepsy syndrome	0.0223	0.0549	CbGbCtD
Sulindac—ALB—Propofol—epilepsy syndrome	0.0208	0.0512	CbGbCtD
Sulindac—PTGS1—Valproic Acid—epilepsy syndrome	0.0199	0.0489	CbGbCtD
Sulindac—ALB—Diazepam—epilepsy syndrome	0.0188	0.0463	CbGbCtD
Sulindac—SLC22A6—Valproic Acid—epilepsy syndrome	0.0174	0.0429	CbGbCtD
Sulindac—CYP1A2—Carbamazepine—epilepsy syndrome	0.0149	0.0366	CbGbCtD
Sulindac—CYP1A2—Primidone—epilepsy syndrome	0.0139	0.0342	CbGbCtD
Sulindac—CYP1A2—Propofol—epilepsy syndrome	0.0124	0.0306	CbGbCtD
Sulindac—CYP1A2—Phenobarbital—epilepsy syndrome	0.0119	0.0292	CbGbCtD
Sulindac—CYP1A2—Diazepam—epilepsy syndrome	0.0113	0.0277	CbGbCtD
Sulindac—CYP1A2—Valproic Acid—epilepsy syndrome	0.00887	0.0219	CbGbCtD
Sulindac—AKR1B1—forebrain—epilepsy syndrome	0.0019	0.0489	CbGeAlD
Sulindac—PTGDR2—cerebellum—epilepsy syndrome	0.00183	0.047	CbGeAlD
Sulindac—AKR1B1—telencephalon—epilepsy syndrome	0.00175	0.045	CbGeAlD
Sulindac—PPARD—forebrain—epilepsy syndrome	0.00149	0.0384	CbGeAlD
Sulindac—PTGDR2—brain—epilepsy syndrome	0.00148	0.0382	CbGeAlD
Sulindac—MAPK3—forebrain—epilepsy syndrome	0.00138	0.0354	CbGeAlD
Sulindac—PPARD—telencephalon—epilepsy syndrome	0.00137	0.0354	CbGeAlD
Sulindac—AKR1B1—medulla oblongata—epilepsy syndrome	0.00137	0.0353	CbGeAlD
Sulindac—MAPK3—telencephalon—epilepsy syndrome	0.00127	0.0326	CbGeAlD
Sulindac—AKR1B1—midbrain—epilepsy syndrome	0.00125	0.0323	CbGeAlD
Sulindac—AKR1B1—spinal cord—epilepsy syndrome	0.00122	0.0315	CbGeAlD
Sulindac—AKR1B1—head—epilepsy syndrome	0.00109	0.028	CbGeAlD
Sulindac—AKR1B1—nervous system—epilepsy syndrome	0.00103	0.0265	CbGeAlD
Sulindac—MAPK3—medulla oblongata—epilepsy syndrome	0.000995	0.0256	CbGeAlD
Sulindac—AKR1B1—central nervous system—epilepsy syndrome	0.000993	0.0256	CbGeAlD
Sulindac—PPARD—midbrain—epilepsy syndrome	0.000986	0.0254	CbGeAlD
Sulindac—AKR1B1—cerebellum—epilepsy syndrome	0.00097	0.025	CbGeAlD
Sulindac—MAPK3—midbrain—epilepsy syndrome	0.000909	0.0234	CbGeAlD
Sulindac—PTGS1—ganglion—epilepsy syndrome	0.000892	0.023	CbGeAlD
Sulindac—MAPK3—spinal cord—epilepsy syndrome	0.000887	0.0228	CbGeAlD
Sulindac—PPARD—head—epilepsy syndrome	0.000855	0.022	CbGeAlD
Sulindac—PPARD—nervous system—epilepsy syndrome	0.000811	0.0209	CbGeAlD
Sulindac—MAPK3—head—epilepsy syndrome	0.000788	0.0203	CbGeAlD
Sulindac—AKR1B1—brain—epilepsy syndrome	0.000788	0.0203	CbGeAlD
Sulindac—PPARD—central nervous system—epilepsy syndrome	0.000781	0.0201	CbGeAlD
Sulindac—PPARD—cerebellum—epilepsy syndrome	0.000763	0.0196	CbGeAlD
Sulindac—MAPK3—nervous system—epilepsy syndrome	0.000747	0.0192	CbGeAlD
Sulindac—MAPK3—central nervous system—epilepsy syndrome	0.00072	0.0185	CbGeAlD
Sulindac—MAPK3—cerebellum—epilepsy syndrome	0.000703	0.0181	CbGeAlD
Sulindac—PPARD—brain—epilepsy syndrome	0.00062	0.016	CbGeAlD
Sulindac—MAPK3—brain—epilepsy syndrome	0.000571	0.0147	CbGeAlD
Sulindac—SLC22A6—brain—epilepsy syndrome	0.000437	0.0112	CbGeAlD
Sulindac—PTGS1—forebrain—epilepsy syndrome	0.000374	0.00963	CbGeAlD
Sulindac—PTGS2—forebrain—epilepsy syndrome	0.000358	0.00921	CbGeAlD
Sulindac—PTGS1—telencephalon—epilepsy syndrome	0.000344	0.00886	CbGeAlD
Sulindac—PTGS2—telencephalon—epilepsy syndrome	0.000329	0.00846	CbGeAlD
Sulindac—ALB—brain—epilepsy syndrome	0.000272	0.00701	CbGeAlD
Sulindac—PTGS2—medulla oblongata—epilepsy syndrome	0.000258	0.00665	CbGeAlD
Sulindac—CYP1A1—head—epilepsy syndrome	0.000244	0.00628	CbGeAlD
Sulindac—PTGS1—spinal cord—epilepsy syndrome	0.000241	0.0062	CbGeAlD
Sulindac—PTGS2—midbrain—epilepsy syndrome	0.000236	0.00608	CbGeAlD
Sulindac—CYP1A1—nervous system—epilepsy syndrome	0.000231	0.00595	CbGeAlD
Sulindac—PTGS2—spinal cord—epilepsy syndrome	0.00023	0.00593	CbGeAlD
Sulindac—CYP1A1—central nervous system—epilepsy syndrome	0.000223	0.00573	CbGeAlD
Sulindac—PTGS1—head—epilepsy syndrome	0.000214	0.00551	CbGeAlD
Sulindac—PTGS2—head—epilepsy syndrome	0.000205	0.00527	CbGeAlD
Sulindac—PTGS1—nervous system—epilepsy syndrome	0.000203	0.00523	CbGeAlD
Sulindac—PTGS1—central nervous system—epilepsy syndrome	0.000196	0.00503	CbGeAlD
Sulindac—PTGS2—nervous system—epilepsy syndrome	0.000194	0.005	CbGeAlD
Sulindac—PTGS2—central nervous system—epilepsy syndrome	0.000187	0.00481	CbGeAlD
Sulindac—PTGS2—cerebellum—epilepsy syndrome	0.000183	0.0047	CbGeAlD
Sulindac—CYP1A1—brain—epilepsy syndrome	0.000177	0.00455	CbGeAlD
Sulindac—PTGS1—brain—epilepsy syndrome	0.000155	0.004	CbGeAlD
Sulindac—PTGS2—brain—epilepsy syndrome	0.000148	0.00382	CbGeAlD
Sulindac—Dysgeusia—Gabapentin—epilepsy syndrome	6.21e-05	0.000311	CcSEcCtD
Sulindac—Dizziness—Diazepam—epilepsy syndrome	6.21e-05	0.000311	CcSEcCtD
Sulindac—Syncope—Pregabalin—epilepsy syndrome	6.2e-05	0.000311	CcSEcCtD
Sulindac—Leukopenia—Pregabalin—epilepsy syndrome	6.19e-05	0.00031	CcSEcCtD
Sulindac—Rash—Fosphenytoin—epilepsy syndrome	6.17e-05	0.000309	CcSEcCtD
Sulindac—Dermatitis—Fosphenytoin—epilepsy syndrome	6.17e-05	0.000309	CcSEcCtD
Sulindac—Nervousness—Gabapentin—epilepsy syndrome	6.16e-05	0.000308	CcSEcCtD
Sulindac—Asthenia—Clonazepam—epilepsy syndrome	6.15e-05	0.000308	CcSEcCtD
Sulindac—Headache—Fosphenytoin—epilepsy syndrome	6.13e-05	0.000307	CcSEcCtD
Sulindac—Hepatitis—Topiramate—epilepsy syndrome	6.13e-05	0.000307	CcSEcCtD
Sulindac—Thrombocytopenia—Valproic Acid—epilepsy syndrome	6.12e-05	0.000306	CcSEcCtD
Sulindac—Palpitations—Pregabalin—epilepsy syndrome	6.11e-05	0.000306	CcSEcCtD
Sulindac—Asthenia—Phenytoin—epilepsy syndrome	6.11e-05	0.000306	CcSEcCtD
Sulindac—Nausea—Midazolam—epilepsy syndrome	6.1e-05	0.000305	CcSEcCtD
Sulindac—Tachycardia—Valproic Acid—epilepsy syndrome	6.1e-05	0.000305	CcSEcCtD
Sulindac—Diarrhoea—Zonisamide—epilepsy syndrome	6.09e-05	0.000305	CcSEcCtD
Sulindac—Loss of consciousness—Pregabalin—epilepsy syndrome	6.08e-05	0.000304	CcSEcCtD
Sulindac—Asthenia—Oxcarbazepine—epilepsy syndrome	6.08e-05	0.000304	CcSEcCtD
Sulindac—Pruritus—Clonazepam—epilepsy syndrome	6.07e-05	0.000304	CcSEcCtD
Sulindac—Vomiting—Vigabatrin—epilepsy syndrome	6.07e-05	0.000304	CcSEcCtD
Sulindac—Hyperhidrosis—Valproic Acid—epilepsy syndrome	6.04e-05	0.000302	CcSEcCtD
Sulindac—Pruritus—Phenytoin—epilepsy syndrome	6.03e-05	0.000302	CcSEcCtD
Sulindac—Nausea—Levetiracetam—epilepsy syndrome	6.02e-05	0.000302	CcSEcCtD
Sulindac—Rash—Vigabatrin—epilepsy syndrome	6.02e-05	0.000301	CcSEcCtD
Sulindac—Dizziness—Felbamate—epilepsy syndrome	6.01e-05	0.000301	CcSEcCtD
Sulindac—Dermatitis—Vigabatrin—epilepsy syndrome	6.01e-05	0.000301	CcSEcCtD
Sulindac—Pruritus—Oxcarbazepine—epilepsy syndrome	6e-05	0.0003	CcSEcCtD
Sulindac—Convulsion—Pregabalin—epilepsy syndrome	5.99e-05	0.0003	CcSEcCtD
Sulindac—Hypersensitivity—Carbamazepine—epilepsy syndrome	5.99e-05	0.0003	CcSEcCtD
Sulindac—Vision blurred—Gabapentin—epilepsy syndrome	5.98e-05	0.000299	CcSEcCtD
Sulindac—Headache—Vigabatrin—epilepsy syndrome	5.98e-05	0.000299	CcSEcCtD
Sulindac—Hypertension—Pregabalin—epilepsy syndrome	5.97e-05	0.000299	CcSEcCtD
Sulindac—Vomiting—Diazepam—epilepsy syndrome	5.97e-05	0.000299	CcSEcCtD
Sulindac—Anorexia—Valproic Acid—epilepsy syndrome	5.95e-05	0.000298	CcSEcCtD
Sulindac—Rash—Diazepam—epilepsy syndrome	5.92e-05	0.000297	CcSEcCtD
Sulindac—Dermatitis—Diazepam—epilepsy syndrome	5.92e-05	0.000296	CcSEcCtD
Sulindac—Visual impairment—Topiramate—epilepsy syndrome	5.91e-05	0.000296	CcSEcCtD
Sulindac—Arthralgia—Pregabalin—epilepsy syndrome	5.89e-05	0.000295	CcSEcCtD
Sulindac—Myalgia—Pregabalin—epilepsy syndrome	5.89e-05	0.000295	CcSEcCtD
Sulindac—Chest pain—Pregabalin—epilepsy syndrome	5.89e-05	0.000295	CcSEcCtD
Sulindac—Ill-defined disorder—Gabapentin—epilepsy syndrome	5.89e-05	0.000295	CcSEcCtD
Sulindac—Dizziness—Zonisamide—epilepsy syndrome	5.89e-05	0.000295	CcSEcCtD
Sulindac—Headache—Diazepam—epilepsy syndrome	5.88e-05	0.000295	CcSEcCtD
Sulindac—Diarrhoea—Clonazepam—epilepsy syndrome	5.87e-05	0.000294	CcSEcCtD
Sulindac—Anaemia—Gabapentin—epilepsy syndrome	5.86e-05	0.000294	CcSEcCtD
Sulindac—Hypotension—Valproic Acid—epilepsy syndrome	5.84e-05	0.000292	CcSEcCtD
Sulindac—Asthenia—Carbamazepine—epilepsy syndrome	5.83e-05	0.000292	CcSEcCtD
Sulindac—Diarrhoea—Phenytoin—epilepsy syndrome	5.83e-05	0.000292	CcSEcCtD
Sulindac—Discomfort—Pregabalin—epilepsy syndrome	5.82e-05	0.000291	CcSEcCtD
Sulindac—Nausea—Fosphenytoin—epilepsy syndrome	5.81e-05	0.000291	CcSEcCtD
Sulindac—Diarrhoea—Oxcarbazepine—epilepsy syndrome	5.8e-05	0.00029	CcSEcCtD
Sulindac—Erythema multiforme—Topiramate—epilepsy syndrome	5.8e-05	0.00029	CcSEcCtD
Sulindac—Angioedema—Gabapentin—epilepsy syndrome	5.8e-05	0.00029	CcSEcCtD
Sulindac—Hypersensitivity—Lamotrigine—epilepsy syndrome	5.79e-05	0.00029	CcSEcCtD
Sulindac—Vomiting—Felbamate—epilepsy syndrome	5.78e-05	0.000289	CcSEcCtD
Sulindac—Pruritus—Carbamazepine—epilepsy syndrome	5.75e-05	0.000288	CcSEcCtD
Sulindac—Rash—Felbamate—epilepsy syndrome	5.73e-05	0.000287	CcSEcCtD
Sulindac—Dermatitis—Felbamate—epilepsy syndrome	5.73e-05	0.000287	CcSEcCtD
Sulindac—Malaise—Gabapentin—epilepsy syndrome	5.72e-05	0.000286	CcSEcCtD
Sulindac—Tinnitus—Topiramate—epilepsy syndrome	5.72e-05	0.000286	CcSEcCtD
Sulindac—Vertigo—Gabapentin—epilepsy syndrome	5.7e-05	0.000285	CcSEcCtD
Sulindac—Headache—Felbamate—epilepsy syndrome	5.7e-05	0.000285	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	5.69e-05	0.000285	CcSEcCtD
Sulindac—Flushing—Topiramate—epilepsy syndrome	5.69e-05	0.000285	CcSEcCtD
Sulindac—Syncope—Gabapentin—epilepsy syndrome	5.69e-05	0.000285	CcSEcCtD
Sulindac—Leukopenia—Gabapentin—epilepsy syndrome	5.68e-05	0.000284	CcSEcCtD
Sulindac—Dizziness—Clonazepam—epilepsy syndrome	5.67e-05	0.000284	CcSEcCtD
Sulindac—Nausea—Vigabatrin—epilepsy syndrome	5.67e-05	0.000284	CcSEcCtD
Sulindac—Vomiting—Zonisamide—epilepsy syndrome	5.66e-05	0.000283	CcSEcCtD
Sulindac—Insomnia—Valproic Acid—epilepsy syndrome	5.65e-05	0.000283	CcSEcCtD
Sulindac—Oedema—Pregabalin—epilepsy syndrome	5.65e-05	0.000283	CcSEcCtD
Sulindac—Anaphylactic shock—Pregabalin—epilepsy syndrome	5.65e-05	0.000283	CcSEcCtD
Sulindac—Asthenia—Lamotrigine—epilepsy syndrome	5.64e-05	0.000282	CcSEcCtD
Sulindac—Dizziness—Phenytoin—epilepsy syndrome	5.63e-05	0.000282	CcSEcCtD
Sulindac—Rash—Zonisamide—epilepsy syndrome	5.61e-05	0.000281	CcSEcCtD
Sulindac—Paraesthesia—Valproic Acid—epilepsy syndrome	5.61e-05	0.000281	CcSEcCtD
Sulindac—Palpitations—Gabapentin—epilepsy syndrome	5.61e-05	0.000281	CcSEcCtD
Sulindac—Dermatitis—Zonisamide—epilepsy syndrome	5.61e-05	0.000281	CcSEcCtD
Sulindac—Dizziness—Oxcarbazepine—epilepsy syndrome	5.6e-05	0.000281	CcSEcCtD
Sulindac—Nausea—Diazepam—epilepsy syndrome	5.58e-05	0.000279	CcSEcCtD
Sulindac—Loss of consciousness—Gabapentin—epilepsy syndrome	5.58e-05	0.000279	CcSEcCtD
Sulindac—Headache—Zonisamide—epilepsy syndrome	5.58e-05	0.000279	CcSEcCtD
Sulindac—Dyspnoea—Valproic Acid—epilepsy syndrome	5.57e-05	0.000279	CcSEcCtD
Sulindac—Diarrhoea—Carbamazepine—epilepsy syndrome	5.56e-05	0.000279	CcSEcCtD
Sulindac—Pruritus—Lamotrigine—epilepsy syndrome	5.56e-05	0.000278	CcSEcCtD
Sulindac—Shock—Pregabalin—epilepsy syndrome	5.56e-05	0.000278	CcSEcCtD
Sulindac—Somnolence—Valproic Acid—epilepsy syndrome	5.55e-05	0.000278	CcSEcCtD
Sulindac—Thrombocytopenia—Pregabalin—epilepsy syndrome	5.53e-05	0.000277	CcSEcCtD
Sulindac—Tachycardia—Pregabalin—epilepsy syndrome	5.51e-05	0.000276	CcSEcCtD
Sulindac—Chills—Topiramate—epilepsy syndrome	5.5e-05	0.000275	CcSEcCtD
Sulindac—Dyspepsia—Valproic Acid—epilepsy syndrome	5.5e-05	0.000275	CcSEcCtD
Sulindac—Convulsion—Gabapentin—epilepsy syndrome	5.5e-05	0.000275	CcSEcCtD
Sulindac—Hypertension—Gabapentin—epilepsy syndrome	5.48e-05	0.000274	CcSEcCtD
Sulindac—Hyperhidrosis—Pregabalin—epilepsy syndrome	5.46e-05	0.000273	CcSEcCtD
Sulindac—Vomiting—Clonazepam—epilepsy syndrome	5.45e-05	0.000273	CcSEcCtD
Sulindac—Decreased appetite—Valproic Acid—epilepsy syndrome	5.43e-05	0.000272	CcSEcCtD
Sulindac—Alopecia—Topiramate—epilepsy syndrome	5.42e-05	0.000271	CcSEcCtD
Sulindac—Vomiting—Phenytoin—epilepsy syndrome	5.42e-05	0.000271	CcSEcCtD
Sulindac—Rash—Clonazepam—epilepsy syndrome	5.41e-05	0.000271	CcSEcCtD
Sulindac—Dermatitis—Clonazepam—epilepsy syndrome	5.4e-05	0.00027	CcSEcCtD
Sulindac—Myalgia—Gabapentin—epilepsy syndrome	5.4e-05	0.00027	CcSEcCtD
Sulindac—Chest pain—Gabapentin—epilepsy syndrome	5.4e-05	0.00027	CcSEcCtD
Sulindac—Arthralgia—Gabapentin—epilepsy syndrome	5.4e-05	0.00027	CcSEcCtD
Sulindac—Nausea—Felbamate—epilepsy syndrome	5.4e-05	0.00027	CcSEcCtD
Sulindac—Vomiting—Oxcarbazepine—epilepsy syndrome	5.39e-05	0.00027	CcSEcCtD
Sulindac—Fatigue—Valproic Acid—epilepsy syndrome	5.38e-05	0.00027	CcSEcCtD
Sulindac—Anorexia—Pregabalin—epilepsy syndrome	5.38e-05	0.000269	CcSEcCtD
Sulindac—Dizziness—Carbamazepine—epilepsy syndrome	5.38e-05	0.000269	CcSEcCtD
Sulindac—Diarrhoea—Lamotrigine—epilepsy syndrome	5.38e-05	0.000269	CcSEcCtD
Sulindac—Headache—Clonazepam—epilepsy syndrome	5.37e-05	0.000269	CcSEcCtD
Sulindac—Rash—Phenytoin—epilepsy syndrome	5.37e-05	0.000269	CcSEcCtD
Sulindac—Dermatitis—Phenytoin—epilepsy syndrome	5.37e-05	0.000269	CcSEcCtD
Sulindac—Rash—Oxcarbazepine—epilepsy syndrome	5.34e-05	0.000268	CcSEcCtD
Sulindac—Constipation—Valproic Acid—epilepsy syndrome	5.34e-05	0.000267	CcSEcCtD
Sulindac—Dermatitis—Oxcarbazepine—epilepsy syndrome	5.34e-05	0.000267	CcSEcCtD
Sulindac—Headache—Phenytoin—epilepsy syndrome	5.34e-05	0.000267	CcSEcCtD
Sulindac—Discomfort—Gabapentin—epilepsy syndrome	5.34e-05	0.000267	CcSEcCtD
Sulindac—Headache—Oxcarbazepine—epilepsy syndrome	5.31e-05	0.000266	CcSEcCtD
Sulindac—Nausea—Zonisamide—epilepsy syndrome	5.29e-05	0.000265	CcSEcCtD
Sulindac—Hypotension—Pregabalin—epilepsy syndrome	5.28e-05	0.000264	CcSEcCtD
Sulindac—Flatulence—Topiramate—epilepsy syndrome	5.26e-05	0.000263	CcSEcCtD
Sulindac—Tension—Topiramate—epilepsy syndrome	5.24e-05	0.000262	CcSEcCtD
Sulindac—Dysgeusia—Topiramate—epilepsy syndrome	5.23e-05	0.000262	CcSEcCtD
Sulindac—Dizziness—Lamotrigine—epilepsy syndrome	5.2e-05	0.00026	CcSEcCtD
Sulindac—Nervousness—Topiramate—epilepsy syndrome	5.18e-05	0.00026	CcSEcCtD
Sulindac—Oedema—Gabapentin—epilepsy syndrome	5.18e-05	0.000259	CcSEcCtD
Sulindac—Anaphylactic shock—Gabapentin—epilepsy syndrome	5.18e-05	0.000259	CcSEcCtD
Sulindac—Vomiting—Carbamazepine—epilepsy syndrome	5.17e-05	0.000259	CcSEcCtD
Sulindac—Feeling abnormal—Valproic Acid—epilepsy syndrome	5.15e-05	0.000258	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	5.14e-05	0.000258	CcSEcCtD
Sulindac—Rash—Carbamazepine—epilepsy syndrome	5.13e-05	0.000257	CcSEcCtD
Sulindac—Dermatitis—Carbamazepine—epilepsy syndrome	5.12e-05	0.000256	CcSEcCtD
Sulindac—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	5.11e-05	0.000256	CcSEcCtD
Sulindac—Insomnia—Pregabalin—epilepsy syndrome	5.11e-05	0.000256	CcSEcCtD
Sulindac—Nausea—Clonazepam—epilepsy syndrome	5.09e-05	0.000255	CcSEcCtD
Sulindac—Headache—Carbamazepine—epilepsy syndrome	5.09e-05	0.000255	CcSEcCtD
Sulindac—Shock—Gabapentin—epilepsy syndrome	5.09e-05	0.000255	CcSEcCtD
Sulindac—Paraesthesia—Pregabalin—epilepsy syndrome	5.07e-05	0.000254	CcSEcCtD
Sulindac—Thrombocytopenia—Gabapentin—epilepsy syndrome	5.07e-05	0.000254	CcSEcCtD
Sulindac—Nausea—Phenytoin—epilepsy syndrome	5.06e-05	0.000253	CcSEcCtD
Sulindac—Tachycardia—Gabapentin—epilepsy syndrome	5.05e-05	0.000253	CcSEcCtD
Sulindac—Dyspnoea—Pregabalin—epilepsy syndrome	5.03e-05	0.000252	CcSEcCtD
Sulindac—Nausea—Oxcarbazepine—epilepsy syndrome	5.03e-05	0.000252	CcSEcCtD
Sulindac—Vision blurred—Topiramate—epilepsy syndrome	5.03e-05	0.000252	CcSEcCtD
Sulindac—Somnolence—Pregabalin—epilepsy syndrome	5.02e-05	0.000251	CcSEcCtD
Sulindac—Hyperhidrosis—Gabapentin—epilepsy syndrome	5.01e-05	0.000251	CcSEcCtD
Sulindac—Vomiting—Lamotrigine—epilepsy syndrome	5e-05	0.00025	CcSEcCtD
Sulindac—Urticaria—Valproic Acid—epilepsy syndrome	4.96e-05	0.000248	CcSEcCtD
Sulindac—Rash—Lamotrigine—epilepsy syndrome	4.96e-05	0.000248	CcSEcCtD
Sulindac—Ill-defined disorder—Topiramate—epilepsy syndrome	4.95e-05	0.000248	CcSEcCtD
Sulindac—Dermatitis—Lamotrigine—epilepsy syndrome	4.95e-05	0.000248	CcSEcCtD
Sulindac—Body temperature increased—Valproic Acid—epilepsy syndrome	4.94e-05	0.000247	CcSEcCtD
Sulindac—Anorexia—Gabapentin—epilepsy syndrome	4.94e-05	0.000247	CcSEcCtD
Sulindac—Anaemia—Topiramate—epilepsy syndrome	4.93e-05	0.000247	CcSEcCtD
Sulindac—Headache—Lamotrigine—epilepsy syndrome	4.92e-05	0.000247	CcSEcCtD
Sulindac—Decreased appetite—Pregabalin—epilepsy syndrome	4.91e-05	0.000246	CcSEcCtD
Sulindac—Fatigue—Pregabalin—epilepsy syndrome	4.87e-05	0.000244	CcSEcCtD
Sulindac—Hypotension—Gabapentin—epilepsy syndrome	4.84e-05	0.000242	CcSEcCtD
Sulindac—Nausea—Carbamazepine—epilepsy syndrome	4.83e-05	0.000242	CcSEcCtD
Sulindac—Constipation—Pregabalin—epilepsy syndrome	4.83e-05	0.000242	CcSEcCtD
Sulindac—Malaise—Topiramate—epilepsy syndrome	4.81e-05	0.000241	CcSEcCtD
Sulindac—Vertigo—Topiramate—epilepsy syndrome	4.8e-05	0.00024	CcSEcCtD
Sulindac—Syncope—Topiramate—epilepsy syndrome	4.79e-05	0.00024	CcSEcCtD
Sulindac—Leukopenia—Topiramate—epilepsy syndrome	4.78e-05	0.000239	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	4.72e-05	0.000236	CcSEcCtD
Sulindac—Palpitations—Topiramate—epilepsy syndrome	4.72e-05	0.000236	CcSEcCtD
Sulindac—Loss of consciousness—Topiramate—epilepsy syndrome	4.69e-05	0.000235	CcSEcCtD
Sulindac—Insomnia—Gabapentin—epilepsy syndrome	4.68e-05	0.000234	CcSEcCtD
Sulindac—Nausea—Lamotrigine—epilepsy syndrome	4.67e-05	0.000234	CcSEcCtD
Sulindac—Feeling abnormal—Pregabalin—epilepsy syndrome	4.65e-05	0.000233	CcSEcCtD
Sulindac—Paraesthesia—Gabapentin—epilepsy syndrome	4.65e-05	0.000233	CcSEcCtD
Sulindac—Convulsion—Topiramate—epilepsy syndrome	4.62e-05	0.000232	CcSEcCtD
Sulindac—Gastrointestinal pain—Pregabalin—epilepsy syndrome	4.62e-05	0.000231	CcSEcCtD
Sulindac—Dyspnoea—Gabapentin—epilepsy syndrome	4.62e-05	0.000231	CcSEcCtD
Sulindac—Hypertension—Topiramate—epilepsy syndrome	4.61e-05	0.000231	CcSEcCtD
Sulindac—Somnolence—Gabapentin—epilepsy syndrome	4.6e-05	0.00023	CcSEcCtD
Sulindac—Hypersensitivity—Valproic Acid—epilepsy syndrome	4.6e-05	0.00023	CcSEcCtD
Sulindac—Dyspepsia—Gabapentin—epilepsy syndrome	4.56e-05	0.000228	CcSEcCtD
Sulindac—Arthralgia—Topiramate—epilepsy syndrome	4.54e-05	0.000227	CcSEcCtD
Sulindac—Chest pain—Topiramate—epilepsy syndrome	4.54e-05	0.000227	CcSEcCtD
Sulindac—Myalgia—Topiramate—epilepsy syndrome	4.54e-05	0.000227	CcSEcCtD
Sulindac—Decreased appetite—Gabapentin—epilepsy syndrome	4.5e-05	0.000225	CcSEcCtD
Sulindac—Discomfort—Topiramate—epilepsy syndrome	4.49e-05	0.000225	CcSEcCtD
Sulindac—Urticaria—Pregabalin—epilepsy syndrome	4.49e-05	0.000225	CcSEcCtD
Sulindac—Asthenia—Valproic Acid—epilepsy syndrome	4.48e-05	0.000224	CcSEcCtD
Sulindac—Fatigue—Gabapentin—epilepsy syndrome	4.46e-05	0.000223	CcSEcCtD
Sulindac—Body temperature increased—Pregabalin—epilepsy syndrome	4.46e-05	0.000223	CcSEcCtD
Sulindac—Constipation—Gabapentin—epilepsy syndrome	4.43e-05	0.000222	CcSEcCtD
Sulindac—Pruritus—Valproic Acid—epilepsy syndrome	4.42e-05	0.000221	CcSEcCtD
Sulindac—Oedema—Topiramate—epilepsy syndrome	4.36e-05	0.000218	CcSEcCtD
Sulindac—Shock—Topiramate—epilepsy syndrome	4.29e-05	0.000215	CcSEcCtD
Sulindac—Diarrhoea—Valproic Acid—epilepsy syndrome	4.27e-05	0.000214	CcSEcCtD
Sulindac—Feeling abnormal—Gabapentin—epilepsy syndrome	4.27e-05	0.000214	CcSEcCtD
Sulindac—Thrombocytopenia—Topiramate—epilepsy syndrome	4.26e-05	0.000214	CcSEcCtD
Sulindac—Tachycardia—Topiramate—epilepsy syndrome	4.25e-05	0.000213	CcSEcCtD
Sulindac—Gastrointestinal pain—Gabapentin—epilepsy syndrome	4.23e-05	0.000212	CcSEcCtD
Sulindac—Hyperhidrosis—Topiramate—epilepsy syndrome	4.21e-05	0.000211	CcSEcCtD
Sulindac—Hypersensitivity—Pregabalin—epilepsy syndrome	4.16e-05	0.000208	CcSEcCtD
Sulindac—Anorexia—Topiramate—epilepsy syndrome	4.15e-05	0.000208	CcSEcCtD
Sulindac—Dizziness—Valproic Acid—epilepsy syndrome	4.13e-05	0.000207	CcSEcCtD
Sulindac—Urticaria—Gabapentin—epilepsy syndrome	4.11e-05	0.000206	CcSEcCtD
Sulindac—Body temperature increased—Gabapentin—epilepsy syndrome	4.09e-05	0.000205	CcSEcCtD
Sulindac—Hypotension—Topiramate—epilepsy syndrome	4.07e-05	0.000204	CcSEcCtD
Sulindac—Asthenia—Pregabalin—epilepsy syndrome	4.05e-05	0.000203	CcSEcCtD
Sulindac—Pruritus—Pregabalin—epilepsy syndrome	3.99e-05	0.0002	CcSEcCtD
Sulindac—Vomiting—Valproic Acid—epilepsy syndrome	3.97e-05	0.000199	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	3.97e-05	0.000199	CcSEcCtD
Sulindac—Insomnia—Topiramate—epilepsy syndrome	3.94e-05	0.000197	CcSEcCtD
Sulindac—Rash—Valproic Acid—epilepsy syndrome	3.94e-05	0.000197	CcSEcCtD
Sulindac—Dermatitis—Valproic Acid—epilepsy syndrome	3.93e-05	0.000197	CcSEcCtD
Sulindac—Headache—Valproic Acid—epilepsy syndrome	3.91e-05	0.000196	CcSEcCtD
Sulindac—Paraesthesia—Topiramate—epilepsy syndrome	3.91e-05	0.000196	CcSEcCtD
Sulindac—Dyspnoea—Topiramate—epilepsy syndrome	3.88e-05	0.000194	CcSEcCtD
Sulindac—Somnolence—Topiramate—epilepsy syndrome	3.87e-05	0.000194	CcSEcCtD
Sulindac—Diarrhoea—Pregabalin—epilepsy syndrome	3.86e-05	0.000193	CcSEcCtD
Sulindac—Dyspepsia—Topiramate—epilepsy syndrome	3.83e-05	0.000192	CcSEcCtD
Sulindac—Hypersensitivity—Gabapentin—epilepsy syndrome	3.81e-05	0.000191	CcSEcCtD
Sulindac—Decreased appetite—Topiramate—epilepsy syndrome	3.79e-05	0.00019	CcSEcCtD
Sulindac—Fatigue—Topiramate—epilepsy syndrome	3.76e-05	0.000188	CcSEcCtD
Sulindac—Dizziness—Pregabalin—epilepsy syndrome	3.73e-05	0.000187	CcSEcCtD
Sulindac—Constipation—Topiramate—epilepsy syndrome	3.72e-05	0.000186	CcSEcCtD
Sulindac—Asthenia—Gabapentin—epilepsy syndrome	3.71e-05	0.000186	CcSEcCtD
Sulindac—Nausea—Valproic Acid—epilepsy syndrome	3.71e-05	0.000186	CcSEcCtD
Sulindac—Pruritus—Gabapentin—epilepsy syndrome	3.66e-05	0.000183	CcSEcCtD
Sulindac—Vomiting—Pregabalin—epilepsy syndrome	3.59e-05	0.00018	CcSEcCtD
Sulindac—Feeling abnormal—Topiramate—epilepsy syndrome	3.59e-05	0.00018	CcSEcCtD
Sulindac—Gastrointestinal pain—Topiramate—epilepsy syndrome	3.56e-05	0.000178	CcSEcCtD
Sulindac—Rash—Pregabalin—epilepsy syndrome	3.56e-05	0.000178	CcSEcCtD
Sulindac—Dermatitis—Pregabalin—epilepsy syndrome	3.56e-05	0.000178	CcSEcCtD
Sulindac—Diarrhoea—Gabapentin—epilepsy syndrome	3.54e-05	0.000177	CcSEcCtD
Sulindac—Headache—Pregabalin—epilepsy syndrome	3.54e-05	0.000177	CcSEcCtD
Sulindac—Urticaria—Topiramate—epilepsy syndrome	3.46e-05	0.000173	CcSEcCtD
Sulindac—Body temperature increased—Topiramate—epilepsy syndrome	3.44e-05	0.000172	CcSEcCtD
Sulindac—Dizziness—Gabapentin—epilepsy syndrome	3.42e-05	0.000171	CcSEcCtD
Sulindac—Nausea—Pregabalin—epilepsy syndrome	3.35e-05	0.000168	CcSEcCtD
Sulindac—Vomiting—Gabapentin—epilepsy syndrome	3.29e-05	0.000165	CcSEcCtD
Sulindac—Rash—Gabapentin—epilepsy syndrome	3.26e-05	0.000163	CcSEcCtD
Sulindac—Dermatitis—Gabapentin—epilepsy syndrome	3.26e-05	0.000163	CcSEcCtD
Sulindac—Headache—Gabapentin—epilepsy syndrome	3.24e-05	0.000162	CcSEcCtD
Sulindac—Hypersensitivity—Topiramate—epilepsy syndrome	3.21e-05	0.000161	CcSEcCtD
Sulindac—Asthenia—Topiramate—epilepsy syndrome	3.13e-05	0.000156	CcSEcCtD
Sulindac—Pruritus—Topiramate—epilepsy syndrome	3.08e-05	0.000154	CcSEcCtD
Sulindac—Nausea—Gabapentin—epilepsy syndrome	3.08e-05	0.000154	CcSEcCtD
Sulindac—Diarrhoea—Topiramate—epilepsy syndrome	2.98e-05	0.000149	CcSEcCtD
Sulindac—Dizziness—Topiramate—epilepsy syndrome	2.88e-05	0.000144	CcSEcCtD
Sulindac—Vomiting—Topiramate—epilepsy syndrome	2.77e-05	0.000139	CcSEcCtD
Sulindac—Rash—Topiramate—epilepsy syndrome	2.75e-05	0.000137	CcSEcCtD
Sulindac—Dermatitis—Topiramate—epilepsy syndrome	2.74e-05	0.000137	CcSEcCtD
Sulindac—Headache—Topiramate—epilepsy syndrome	2.73e-05	0.000137	CcSEcCtD
Sulindac—Nausea—Topiramate—epilepsy syndrome	2.59e-05	0.00013	CcSEcCtD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	5.23e-06	3.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—epilepsy syndrome	5.2e-06	3.65e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—YWHAZ—epilepsy syndrome	5.2e-06	3.64e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TXNRD1—epilepsy syndrome	5.17e-06	3.62e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—epilepsy syndrome	5.15e-06	3.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL12—epilepsy syndrome	5.14e-06	3.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BDKRB2—epilepsy syndrome	5.14e-06	3.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—epilepsy syndrome	5.14e-06	3.6e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	5.14e-06	3.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	5.12e-06	3.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PRKCB—epilepsy syndrome	5.12e-06	3.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—epilepsy syndrome	5.1e-06	3.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSD17B4—epilepsy syndrome	5.1e-06	3.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6ST—epilepsy syndrome	5.1e-06	3.57e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—AVP—epilepsy syndrome	5.09e-06	3.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CRP—epilepsy syndrome	5.07e-06	3.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TSC2—epilepsy syndrome	5.07e-06	3.55e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	5.05e-06	3.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUNB—epilepsy syndrome	5.05e-06	3.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CNR1—epilepsy syndrome	5.05e-06	3.54e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP2D6—epilepsy syndrome	5.04e-06	3.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CCR5—epilepsy syndrome	5.03e-06	3.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PLCB1—epilepsy syndrome	5.03e-06	3.52e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AQP1—epilepsy syndrome	5.02e-06	3.52e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—KCNJ11—epilepsy syndrome	4.98e-06	3.49e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CHRM3—epilepsy syndrome	4.98e-06	3.49e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	4.93e-06	3.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GBE1—epilepsy syndrome	4.93e-06	3.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPP1R3C—epilepsy syndrome	4.93e-06	3.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HTR7—epilepsy syndrome	4.92e-06	3.45e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	4.89e-06	3.43e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	4.82e-06	3.38e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	4.82e-06	3.37e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ADRA2A—epilepsy syndrome	4.8e-06	3.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HBEGF—epilepsy syndrome	4.78e-06	3.35e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—BCHE—epilepsy syndrome	4.78e-06	3.35e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	4.76e-06	3.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—SRC—epilepsy syndrome	4.72e-06	3.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT3—epilepsy syndrome	4.69e-06	3.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TSC2—epilepsy syndrome	4.68e-06	3.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PRKCB—epilepsy syndrome	4.68e-06	3.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—POMC—epilepsy syndrome	4.66e-06	3.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6ST—epilepsy syndrome	4.66e-06	3.26e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	4.64e-06	3.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ASAH1—epilepsy syndrome	4.63e-06	3.25e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PLAU—epilepsy syndrome	4.62e-06	3.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ADAM10—epilepsy syndrome	4.58e-06	3.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—APOE—epilepsy syndrome	4.58e-06	3.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCG2—epilepsy syndrome	4.57e-06	3.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL2—epilepsy syndrome	4.56e-06	3.2e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC2A1—epilepsy syndrome	4.56e-06	3.19e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	4.54e-06	3.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CHRM3—epilepsy syndrome	4.54e-06	3.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—KCNJ11—epilepsy syndrome	4.54e-06	3.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STXBP1—epilepsy syndrome	4.51e-06	3.16e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PLCB1—epilepsy syndrome	4.51e-06	3.16e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TH—epilepsy syndrome	4.49e-06	3.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—epilepsy syndrome	4.46e-06	3.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP2C19—epilepsy syndrome	4.46e-06	3.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP11A1—epilepsy syndrome	4.43e-06	3.1e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	4.42e-06	3.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	4.4e-06	3.08e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALAD—epilepsy syndrome	4.39e-06	3.08e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NT5E—epilepsy syndrome	4.39e-06	3.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—S100B—epilepsy syndrome	4.33e-06	3.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC2A1—epilepsy syndrome	4.32e-06	3.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6ST—epilepsy syndrome	4.3e-06	3.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SOCS3—epilepsy syndrome	4.29e-06	3.01e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PRKCB—epilepsy syndrome	4.29e-06	3.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—JUNB—epilepsy syndrome	4.29e-06	3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDC42—epilepsy syndrome	4.28e-06	3e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FOS—epilepsy syndrome	4.27e-06	2.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS2—epilepsy syndrome	4.27e-06	2.99e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS1—epilepsy syndrome	4.26e-06	2.98e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS2—epilepsy syndrome	4.24e-06	2.97e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	4.23e-06	2.96e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	4.22e-06	2.96e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	4.19e-06	2.94e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	4.19e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CASP8—epilepsy syndrome	4.17e-06	2.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AVP—epilepsy syndrome	4.14e-06	2.9e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	4.14e-06	2.9e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	4.1e-06	2.87e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCG2—epilepsy syndrome	4.06e-06	2.84e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HBEGF—epilepsy syndrome	4.06e-06	2.84e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADSL—epilepsy syndrome	4.02e-06	2.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	4.01e-06	2.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP2D6—epilepsy syndrome	4e-06	2.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT3—epilepsy syndrome	3.98e-06	2.79e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP2C19—epilepsy syndrome	3.96e-06	2.77e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GLUL—epilepsy syndrome	3.94e-06	2.76e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP11A1—epilepsy syndrome	3.93e-06	2.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HES1—epilepsy syndrome	3.92e-06	2.75e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.9e-06	2.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ADAM10—epilepsy syndrome	3.89e-06	2.73e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	3.87e-06	2.71e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—epilepsy syndrome	3.85e-06	2.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FYN—epilepsy syndrome	3.81e-06	2.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ADRA2A—epilepsy syndrome	3.81e-06	2.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—H2AFX—epilepsy syndrome	3.8e-06	2.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MEF2C—epilepsy syndrome	3.79e-06	2.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—BCHE—epilepsy syndrome	3.79e-06	2.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FGF2—epilepsy syndrome	3.77e-06	2.64e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HMOX1—epilepsy syndrome	3.75e-06	2.62e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCG2—epilepsy syndrome	3.7e-06	2.59e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAT—epilepsy syndrome	3.7e-06	2.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—YWHAZ—epilepsy syndrome	3.66e-06	2.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDC42—epilepsy syndrome	3.64e-06	2.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NGF—epilepsy syndrome	3.62e-06	2.54e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	3.62e-06	2.53e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC2A1—epilepsy syndrome	3.62e-06	2.53e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP2C19—epilepsy syndrome	3.61e-06	2.53e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ABCB1—epilepsy syndrome	3.6e-06	2.52e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP11A1—epilepsy syndrome	3.58e-06	2.51e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2—epilepsy syndrome	3.58e-06	2.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLCB1—epilepsy syndrome	3.58e-06	2.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TH—epilepsy syndrome	3.56e-06	2.5e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	3.56e-06	2.49e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.56e-06	2.49e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP2D6—epilepsy syndrome	3.55e-06	2.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR5—epilepsy syndrome	3.52e-06	2.47e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AQP1—epilepsy syndrome	3.51e-06	2.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RELA—epilepsy syndrome	3.5e-06	2.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—FGF2—epilepsy syndrome	3.48e-06	2.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HTR2A—epilepsy syndrome	3.45e-06	2.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MTOR—epilepsy syndrome	3.43e-06	2.4e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ADRA2A—epilepsy syndrome	3.38e-06	2.37e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	3.37e-06	2.36e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—BCHE—epilepsy syndrome	3.36e-06	2.36e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GPX1—epilepsy syndrome	3.34e-06	2.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HES1—epilepsy syndrome	3.33e-06	2.33e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—epilepsy syndrome	3.33e-06	2.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—epilepsy syndrome	3.32e-06	2.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TSC2—epilepsy syndrome	3.28e-06	2.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AGT—epilepsy syndrome	3.27e-06	2.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—epilepsy syndrome	3.26e-06	2.28e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FYN—epilepsy syndrome	3.24e-06	2.27e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP2D6—epilepsy syndrome	3.24e-06	2.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—H2AFX—epilepsy syndrome	3.23e-06	2.26e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC2A1—epilepsy syndrome	3.21e-06	2.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOE—epilepsy syndrome	3.21e-06	2.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	3.18e-06	2.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	3.18e-06	2.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLCB1—epilepsy syndrome	3.17e-06	2.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTOR—epilepsy syndrome	3.17e-06	2.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TH—epilepsy syndrome	3.16e-06	2.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—epilepsy syndrome	3.16e-06	2.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KDR—epilepsy syndrome	3.14e-06	2.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—epilepsy syndrome	3.14e-06	2.2e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	3.11e-06	2.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—YWHAZ—epilepsy syndrome	3.11e-06	2.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ADRA2A—epilepsy syndrome	3.08e-06	2.16e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—BCHE—epilepsy syndrome	3.07e-06	2.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—epilepsy syndrome	3.06e-06	2.15e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	3.04e-06	2.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PRKCB—epilepsy syndrome	3.02e-06	2.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6ST—epilepsy syndrome	3.01e-06	2.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CCR5—epilepsy syndrome	2.99e-06	2.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HMOX1—epilepsy syndrome	2.97e-06	2.08e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.96e-06	2.07e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAT—epilepsy syndrome	2.93e-06	2.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—epilepsy syndrome	2.93e-06	2.05e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AGT—epilepsy syndrome	2.93e-06	2.05e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC2A1—epilepsy syndrome	2.93e-06	2.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.9e-06	2.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLCB1—epilepsy syndrome	2.89e-06	2.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TH—epilepsy syndrome	2.88e-06	2.02e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOE—epilepsy syndrome	2.87e-06	2.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—epilepsy syndrome	2.86e-06	2e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.84e-06	1.99e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TSC2—epilepsy syndrome	2.78e-06	1.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—POMC—epilepsy syndrome	2.75e-06	1.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—epilepsy syndrome	2.75e-06	1.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOE—epilepsy syndrome	2.72e-06	1.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—epilepsy syndrome	2.7e-06	1.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPX1—epilepsy syndrome	2.65e-06	1.86e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMOX1—epilepsy syndrome	2.64e-06	1.85e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAT—epilepsy syndrome	2.6e-06	1.82e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	2.59e-06	1.81e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—epilepsy syndrome	2.59e-06	1.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6ST—epilepsy syndrome	2.56e-06	1.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—epilepsy syndrome	2.54e-06	1.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—epilepsy syndrome	2.54e-06	1.78e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—epilepsy syndrome	2.53e-06	1.78e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	2.52e-06	1.77e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—epilepsy syndrome	2.52e-06	1.77e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	2.51e-06	1.76e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.49e-06	1.74e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—POMC—epilepsy syndrome	2.47e-06	1.73e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—epilepsy syndrome	2.46e-06	1.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGF2—epilepsy syndrome	2.44e-06	1.71e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMOX1—epilepsy syndrome	2.41e-06	1.69e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAT—epilepsy syndrome	2.37e-06	1.66e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPX1—epilepsy syndrome	2.36e-06	1.65e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AGT—epilepsy syndrome	2.33e-06	1.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—epilepsy syndrome	2.31e-06	1.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOE—epilepsy syndrome	2.28e-06	1.6e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.27e-06	1.59e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	2.26e-06	1.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RELA—epilepsy syndrome	2.26e-06	1.58e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—epilepsy syndrome	2.25e-06	1.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—epilepsy syndrome	2.22e-06	1.55e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	2.15e-06	1.51e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPX1—epilepsy syndrome	2.15e-06	1.5e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—epilepsy syndrome	2.15e-06	1.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGF2—epilepsy syndrome	2.07e-06	1.45e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AGT—epilepsy syndrome	2.07e-06	1.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	2.05e-06	1.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—epilepsy syndrome	2.04e-06	1.43e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	2.02e-06	1.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOE—epilepsy syndrome	2.02e-06	1.42e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TH—epilepsy syndrome	2.02e-06	1.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.99e-06	1.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—epilepsy syndrome	1.98e-06	1.39e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—epilepsy syndrome	1.97e-06	1.38e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POMC—epilepsy syndrome	1.96e-06	1.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—epilepsy syndrome	1.93e-06	1.35e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—epilepsy syndrome	1.88e-06	1.32e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AGT—epilepsy syndrome	1.88e-06	1.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—epilepsy syndrome	1.87e-06	1.31e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOE—epilepsy syndrome	1.84e-06	1.29e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—epilepsy syndrome	1.79e-06	1.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—epilepsy syndrome	1.78e-06	1.24e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POMC—epilepsy syndrome	1.74e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—epilepsy syndrome	1.73e-06	1.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—epilepsy syndrome	1.71e-06	1.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—epilepsy syndrome	1.7e-06	1.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.68e-06	1.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.66e-06	1.16e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—epilepsy syndrome	1.59e-06	1.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POMC—epilepsy syndrome	1.58e-06	1.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—epilepsy syndrome	1.58e-06	1.1e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—epilepsy syndrome	1.57e-06	1.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—epilepsy syndrome	1.51e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPX1—epilepsy syndrome	1.5e-06	1.05e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—epilepsy syndrome	1.39e-06	9.71e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AGT—epilepsy syndrome	1.32e-06	9.23e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOE—epilepsy syndrome	1.29e-06	9.04e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—epilepsy syndrome	1.26e-06	8.86e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POMC—epilepsy syndrome	1.11e-06	7.77e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—epilepsy syndrome	1.1e-06	7.74e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—epilepsy syndrome	1.01e-06	7.08e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—epilepsy syndrome	9.89e-07	6.93e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—epilepsy syndrome	9.38e-07	6.57e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	8.84e-07	6.19e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—epilepsy syndrome	7.85e-07	5.5e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—epilepsy syndrome	6.97e-07	4.88e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—epilepsy syndrome	6.35e-07	4.45e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—epilepsy syndrome	4.44e-07	3.11e-06	CbGpPWpGaD
